Tier 3 — preclinical

Long-term dasatinib plus quercetin effects on aging outcomes and inflammation in nonhuman primates: implications for senolytic clinical trial design

Alistaire D Ruggiero, Ravichandra Vemuri, Megan Blawas, Masha Long, Darla DeStephanis, Abigail G Williams, Haiying Chen, Jamie N Justice, Shannon L Macauley, Steven M Day, Kylie Kavanagh
GeroScience 2023 45(5):2785-2803

Bibliography

PubMed
PMID 37261678
PubMed Central
PMC10643765
DOI
10.1007/s11357-023-00830-5
Funding
Indexed grant support: P40 OD010965 — NIH HHS — United States; T35 OD010946 — NIH HHS — United States; P30 AG013319 — NIA NIH HHS — United States; R01 HL142930 — NHLBI NIH HHS — United States; P20 GM148326 — NIGMS NIH HHS — United States; R01 AG068330 — NIA NIH HHS — United States; T32 AA007565 — NIAAA NIH HHS — United States; T32 AI007401 — NIAID NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignControlled nonhuman-primate senolytic intervention
ModelAnimal and laboratory research
Sample16 middle-aged primates; 9 D+Q and 7 vehicle
InterventionDasatinib 5 mg/kg plus quercetin 50 mg/kg on two consecutive days each month; calorie restriction added in month 6
Duration6 months
EndpointsInflammatory measures; Senescence-related measurements

What the study showed, in plain terms

Published in 2023, this source examined senescence and longevity. Design: Controlled nonhuman-primate senolytic intervention. Sample/model: 16 middle-aged primates; 9 D+Q and 7 vehicle. The exposure or intervention was Dasatinib 5 mg/kg plus quercetin 50 mg/kg on two consecutive days each month; calorie restriction added in month 6. Follow-up or treatment period: 6 months.

Selected adipose senescence, inflammatory, and organ-health markers improved; some metabolic findings depended on calorie restriction.

Preclinical primate study with small groups and a second intervention. It does not establish human safety, lifespan extension, or quercetin-only efficacy.

Continue with Quercetin Data Center

For topic-level interpretation, read Is Quercetin a Senolytic? Human Evidence vs Longevity Claims. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected adipose senescence, inflammatory, and organ-health markers improved; some metabolic findings depended on calorie restriction.
  • The recorded outcome domains were Inflammatory measures; Senescence-related measurements.
  • The result applies to the tested exposure: Dasatinib 5 mg/kg plus quercetin 50 mg/kg on two consecutive days each month; calorie restriction added in month 6; 6 months.

What this study can and cannot tell us

  • Preclinical primate study with small groups and a second intervention. It does not establish human safety, lifespan extension, or quercetin-only efficacy.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Senolytics improve physical function and increase lifespan in old age
Ming Xu et al. · Nature medicine · 2018
Tier 3
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Yi Zhu et al. · Aging cell · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology